RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients

International Journal of Oncology

Volumn 32, Issue 2, 2008, Pages 481-490

  Napoletano, Chiara ^a   Taurino, Federica ^a   Biffoni, Mauro ^b   De Majo, Adriano ^c   Coscarella, Giorgio ^c   Bellati, Filippo ^a   Rahimi, Hassan ^a   Pauselli, Simona ^a   Pellicciotta, Ilenia ^a   Burchell, Joy M ^d   Gaspari, Lucio Achille ^c   Ercoli, Lucia ^c   Rossi, Piero ^c   Rughetti, Aurelia ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d GUY S HOSPITAL   (United Kingdom)

Author keywords

Anti tumor immune response; Hepatocellular carcinoma; Immunotherapy; Lymphocyte subset; Metastatic liver lesions; MUC1; Radiofrequency tumor ablation

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; L SELECTIN; MUCIN 1; PHYTOHEMAGGLUTININ;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; LIVER CANCER; LIVER CELL CARCINOMA; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY T LYMPHOCYTE; METASTASIS POTENTIAL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TUMOR IMMUNITY;

EID: 38849202426     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.2.481     Document Type: Article

References (39)

1. Blum HE: Treatment of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 19: 129-145, 2005.
2. Tateishi R, Shiina S, Teratani T, et al: Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 103: 1201-1209, 2005.
3. Goldberg SN, Gazelle GS, Compton CC, Mueller PR and Tanabe KK: Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 88: 2452-2463, 2000.
4. McGahan JP, Brock JM, Tesluk H, Gu WZ, Schneider P and Browning PD: Hepatic ablation with use of radiofrequency electrocautery in the animal model. J Vasc Interv Radiol 3: 291-297, 1992.
5. Ng KK and Poon RT: Radiofrequency ablation for malignant liver tumor. Surg Oncol 14: 41-52, 2005.
6. Lu DS, Yu NC, Raman SS, et al: Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 41:1130-1137, 2005.
7. Berber E, Pelley R and Siperstein AE: Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 23: 1358-1364, 2005.
8. Den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ and Adema GJ: In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 64: 4024-4029, 2004.
9. Wissniowski TT, Hansler J, Neureiter D, et al: Activation of tumor-specific T lymphocytes by radiofrequency ablation of the VX2 hepatoma in rabbits. Cancer Res 63: 6496-6500, 2003.
10. Zerbini A, Pilli M, Penna A, et al: Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 66: 1139-1146, 2006.
11. Hansler J, Wissniowski TT, Schuppan D, Witte A, Bernatik T, Hahn EG and Strobel D: Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radiofrequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol 12: 3716-3721, 2006.
12. Livraghi T, Lazzaroni S, Meloni F, et al: Risk of tumour seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma. Br J Surg 92: 856-858, 2005.
13. Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D and Smith M: MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 7: 209-221, 2002.
14. Karsten U, Diotel C, Klich G, Paulsen H, Goletz S, Muller S and Hanisch FG: Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation. Cancer Res 15: 2541-2549, 1998.
15. Bukh J, Miller RH and Purcell RH: Biology and genetic heterogeneity of hepatitis C virus. Clin Exp Rheumatol 13: 3-7, 1995.
16. Hengel RL, Thaker V, Pavlick MV, et al: Cutting edge: L-Selectin (CD62L) expression distinguishes small resting memory CD4+ T cells that preferentially respond to recall antigen. J Immunol 170: 28-32, 2003.
17. Poston GJ: Radiofrequency ablation of colorectal liver metastases: where we really going? J Clin Oncol 23: 1342-1344, 2005.
18. Oshowo A, Gillams AR, Harrison E, Lees WR and Taylor I: Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 90: 1240-1243, 2003.
19. Livraghi T, Solbiati L, Meloni F, et al: Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the 'test-of-time approach'. Cancer 97: 3027-3035, 2003.
20. Bartholomae WC, Rininsland FH, Eisenberg JC, Boehm BO, Lehmann PV and Tary-Lehmann M: T cell immunity induced by live, necrotic and apoptotic tumor cells. J Immunol 73: 1012-1022, 2004.
21. Yang WL, Nair DG, Makizumi R, Gallos G, Ye X, Sharma RR and Ravikumar TS: Heat shock protein 70 is induced in mouse human colon tumor xenografts after sublethal radiofrequency ablation. Ann Surg Oncol 11: 399-406, 2004.
22. Rughetti A, Rahimi H, Rossi P, et al: Modulation of blood circulating immune cells by radiofrequency tumor ablation. J Exp Clin Cancer Res 22: 247-250, 2003.
23. Acres B and Limacher JM: MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 4: 493-502, 2005.
24. Xu Y, Gendler S and Franco A: Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J Exp Med 199: 707-716, 2004.
25. Tarp MA, Sorensen AL, Mandel U, Paulsen H, Burchell J, Taylor-Papadimitriou and Clausen H: Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 17: 197-209, 2007.
26. Rughetti A, Turchi V, Ghetti CA, et al: Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 53: 2457-2459, 1993.
27. Von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, et al: Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18: 574-583, 2000.
28. Ravindranath MH, Wood TF, Soh D, et al: Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments antiganglioside IgM. Cryobiology 45: 10-21, 2002.
29. Ryungsa K, Manabu E and Kazuaki T: Tumor driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66: 5527-5536, 2006.
30. Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274, 2005.
31. Den Brok MH, Sutmuller RP, Nierkens S, et al: Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 95: 896-905, 2006.
32. Gillams AR and Lees WR: Survival after percutaneous, image-guided, thermal ablation of hepatic metastases from colorectal cancer. Dis Colon Rectum 43: 656-661, 2000.
33. Abdalla EK, Vauthey JN, Ellis LM, et al: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239: 818-827, 2004.
34. Golden-Mason L and Rosen HR: Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transpl 12: 363-372, 2006.
35. Gremion C and Cerny A: Hepatitis C virus and the immune system: a concise review. Rev Med Virol 15: 235-268, 2005.
36. Ochesenbein AF: Immunological ignorance of solid tumors. Springer Semin Immunol 27: 19-35, 2005.
37. Zinkernagel RM and Hengartner H: Regulation of the immune response by antigen. Science 293: 251, 2001.
38. Blais ME, Louis I and Perreault C: T-cell development: an extrathymic perspective. Immunol Rev 209: 103-114, 2006.
39. Rose SC, Thistlethwaite PA, Sewell PE and Vance RB: Lung cancer and radiofrequency ablation. J Vasc Interv Radiol 7: 927-951, 2006.